On August 11, Zura Bio (NASDAQ:ZURA) reported second-quarter results that landed on an unusual mix of good and bad news. The clinical-stage biotech finished enrolling two separate Phase 2 studies of its lead drug, tibulizumab, both ahead of their original targets, while a widening net loss showed just how much it costs to run them. The company also named a third disease it wants to chase with the same molecule. Here is what the numbers and the pipeline updates actually say.
Two Trials, One Confident Bet
Tibulizumab is designed to block both interleukin-17 and B-cell activating factor at once, and Zura just proved it can recruit patients around that idea faster than planned. The TibuSHIELD study in hidradenitis suppurativa closed enrollment with 247 participants, above its original target, and topline data are expected in the fourth quarter of 2026. TibuSURE, testing the same drug in systemic sclerosis, finished with 91 participants, also above target, with results expected in the first half of 2027. Beating enrollment goals on two separate trials at the same time is not a small operational feat for a company this size.
Zura is not stopping at two diseases either. It picked polymyalgia rheumatica as tibulizumab’s third indication, a condition that affects north of 700,000 Americans and currently leaves most patients stuck on long-term steroids, with a median time of about six years before they can quit glucocorticoids for good. The company says the FDA gave constructive and supportive feedback on its plan, and it intends to start the NEXUS-PMR study by the end of 2026. Meanwhile, cash and equivalents stood at $205.1 million as of June 30, which management says covers planned operations through at least the end of 2028. That funding runway means Zura can chase three separate readouts without needing to raise money in the middle of any of them.
Burn Rate Picks Up Speed
Running three mid-stage programs costs money, and Zura’s income statement shows it. Research and development expenses came to $20.7 million in the quarter, more than double the $8.7 million spent a year earlier, as the company advanced its Phase 2 tibulizumab trials. General and administrative costs actually fell, to $8.6 million from $9.4 million, on lower professional fees, but that was not enough to offset the R&D jump. Net loss widened to $26.3 million, or $0.21 per share, from $16.0 million, or $0.17 per share, in the same quarter last year.
None of this spending has produced a proven drug yet. Tibulizumab remains investigational and has not been approved by the FDA or any other regulator, so everything rests on trial results still to come. The company also disclosed it is still weighing potential development approaches for its other two clinical candidates, torudokimab and crebankitug, language that leaves open whether either program keeps moving at its current pace. With three separate indications now in play for a single molecule, the company is also spreading its scientific and financial attention across more bets at once.
Money Managers Head For Exits
Hedge fund ownership of Zura Bio fell from 33 funds to 24 in the most recent quarter, a pullback that suggests some institutional holders trimmed their positions rather than added to them. Short interest sits at 15.95% of the float, a level high enough to reflect real organized skepticism about the stock. That combination points to a market that is not yet convinced by the enrollment news, even as it waits on the fourth-quarter data.
What Q4 Will Decide
Zura Bio has done what it said it would do operationally, filling two trials ahead of schedule and lining up a funding cushion into 2028. But operational execution is not the same as clinical proof, and the widening net loss shows what that execution costs before any data exists. The open question is whether tibulizumab’s dual mechanism translates into results strong enough to justify the spending, starting with the HS readout due in the fourth quarter of 2026. If TibuSHIELD delivers, the enrollment story becomes a real catalyst; if it does not, the falling hedge fund count and elevated short interest will look like they saw it coming.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Hedge Fund Resource Center